Buparlisib
Buparlisib
Buparlisib (pronounced boo-par-li-sib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor used in the treatment of various types of cancer. It is also known by its trade name BKM120.
Etymology
The name "Buparlisib" is derived from the chemical structure of the drug, which includes a bupar group and a lisib group. The "-ib" suffix is commonly used in the names of small molecule inhibitors, indicating its function as a PI3K inhibitor.
Usage
Buparlisib is used in the treatment of breast cancer, lung cancer, and other types of cancer. It works by inhibiting the PI3K pathway, which is often overactive in cancer cells, leading to uncontrolled cell growth and proliferation.
Related Terms
- Phosphatidylinositol 3-kinase: A family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.
- Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
- Breast cancer: A cancer that forms in the cells of the breasts.
- Lung cancer: A type of cancer that begins in the lungs.
External links
- Medical encyclopedia article on Buparlisib
- Wikipedia's article - Buparlisib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski